REG - Oxford BioDynamics - Board Appointment

Oxford BiodynamicsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260415:nRSO4812Aa&default-theme=true

RNS Number : 4812A  Oxford BioDynamics PLC  15 April 2026

 

 

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Board Appointment

Oxford, UK - 15 April 2026 - Oxford BioDynamics Plc (AIM: OBD), a precision
clinical diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch® 3D genomics platform, is pleased
to announce the appointment of Martin Diggle as a Non-Executive Director with
effect from 15 April 2026.

Martin was nominated by Vulpes Investment Management, the Company's largest
shareholder through the Vulpes Testudo fund and the Vulpes Life Sciences fund,
replacing Stephen Diggle who stepped down as a Director of the Company on 26
January 2026. Martin is the co-founder of Vulpes Investment Management, and
Chairman and director of the Vulpes Life Sciences fund.

Martin has extensive experience in the life sciences sector and has served on
the Board of several public and privately listed companies such as Oxford
Biomedica, Scancell, Proteome Sciences, Leucid Bio, Chronos Therapeutics and
Oxford Endovascular. Prior to Vulpes, he was a Partner and Director of
UBS/Brunswick. Before that, he spent 7 years at Morgan Stanley. Martin
graduated from the University of Oxford with a Masters in Philosophy, Politics
and Economics.

Executive Chairman Iain Ross said: "Martin brings a wealth of capital markets
and life sciences expertise to the Board. I am thankful for his and Vulpes'
ongoing support towards OBD and look forward to working together."

-Ends-

For further details please contact:

  Oxford BioDynamics Plc                                   Tel: +44 (0)1865 518910
  Iain Ross, Executive Chairman

  Paul Stockdale, CFO
  Singer Capital Markets - Nominated Adviser and Broker    Tel: +44 (0)20 7496 3000
  Phil Davies / Anastassiya Eley
  OAK Securities - Joint Broker                            Tel: +44 (0)20 3973 3678
  Matthew Clarke / Tim Dainton / Calvin Man
  Camarco - Financial PR                                   Tel: +44 (0)20 3757 4980
  Marc Cohen / Tilly Butcher / Fergus Young                OBDFinancial@camarco.co.uk

 

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://protect.checkpoint.com/v2/r02/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6NzowMDMzOmY4Y2Q3OTViOGUzNmI4OTAyZDdiNTgyYjUyMTg4NTFmNDU3Zjc2Yzg5MGY4MzMwMGIwMTkyNTJmOGIyMjIxYzM6cDpUOk4)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://protect.checkpoint.com/v2/r02/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6NzpmZWMxOjk5YTcyZWIyODkyNjI5MDY3MjhiODMwYzgwYjAzZjIzYjljNjI1ZGVlZjJmZGI3ODg1N2IzNmNhMTc3NjM5NTQ6cDpUOk4)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://protect.checkpoint.com/v2/r02/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6NzphNGVlOmZlNjM2YTAxY2E3OTIyZGJmNDZmZmZkOGUxNDc3MjVmMmE4YmVjNzFjYWE5NDg0ZWQwNGEyODAwZWEzNzJjNzM6cDpUOk4)
,  X (@OxBioDynamics) or LinkedIn
(https://protect.checkpoint.com/v2/r02/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6Nzo2NmRmOjBjYzFhMTMyNDVmMDA0MjM4NmQ3YTZiN2E4NWUxODEzOWU5OWQyYzk0NDM3NjgzYTIwNjQ3NTc0NWQ4MWQyYmM6cDpUOk4)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABZLLFQZLZBBK



            Copyright 2019 Regulatory News Service, all rights reserved